GRI Bio (GRI) to Release Earnings on Thursday

GRI Bio (NASDAQ:GRI) is projected to announce its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($6.80) per share for the quarter.

GRI Bio Stock Performance

NASDAQ:GRI opened at $6.70 on Wednesday. GRI Bio has a fifty-two week low of $5.12 and a fifty-two week high of $176.80. The firm has a market cap of $3.52 million, a PE ratio of -0.58 and a beta of -2.10. The business has a 50 day moving average price of $8.67 and a 200-day moving average price of $10.61.

Analyst Upgrades and Downgrades

GRI has been the subject of a number of research reports. HC Wainwright began coverage on shares of GRI Bio in a research note on Monday, December 9th. They issued a “buy” rating and a $170.00 price target for the company. Ascendiant Capital Markets boosted their price objective on shares of GRI Bio from $204.00 to $221.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th.

About GRI Bio

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.